{"id":192789,"name":"BIOCOM","slug":"biocom","state":"CA","country":"United States of America","description":"","totalSpending":2101600,"filings":34,"yearlySpending":[{"year":2018,"income":183600},{"year":2019,"income":213000},{"year":2020,"income":250000},{"year":2021,"income":180000},{"year":2022,"income":300000},{"year":2023,"income":300000},{"year":2024,"income":300000},{"year":2025,"income":375000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"BUD","display":"Budget/Appropriations"},{"code":"TAX","display":"Taxation/Internal Revenue Code"},{"code":"CPT","display":"Copyright/Patent/Trademark"},{"code":"ENG","display":"Energy/Nuclear"},{"code":"TRD","display":"Trade (domestic/foreign)"},{"code":"SMB","display":"Small Business"},{"code":"LBR","display":"Labor Issues/Antitrust/Workplace"},{"code":"IMM","display":"Immigration"},{"code":"AGR","display":"Agriculture"},{"code":"ECN","display":"Economics/Economic Development"}],"firms":["BIOCOM"],"lobbyists":["LAURE CLARK","RICHARD WHITE","MEGAN KASTNER"],"govEntities":["Food & Drug Administration (FDA)","HOUSE OF REPRESENTATIVES","Natl Institutes of Health (NIH)","Patent & Trademark Office (PTO)","SENATE","Health & Human Services, Dept of (HHS)","Commerce, Dept of (DOC)","Small Business Administration (SBA)","Treasury, Dept of","U.S. Trade Representative (USTR)","Centers For Medicare and Medicaid Services (CMS)","Office of Science & Technology Policy (OSTP)","Agriculture, Dept of (USDA)","Environmental Protection Agency (EPA)","Government Accountability Office (GAO)"],"sampleDescriptions":["Hosted an advocacy fly-in about regenerative medicine\nDiscussed how the life science community can help address the opioid crisis \nSupported expanded coverage of whole-genome sequencing\nAdvocated for ","Advocated for increased funding for NIH and FDA in FY2018 omnibus.","Advocated for the suspension of the medical device tax.","Advocated for reforms of IPR proceedings at the PTAB, including support of the STRONGER Patents Act","Advocated for increased funding for NIH and FDA in FY2019 appropriations."]}